[go: up one dir, main page]

AR030021A1 - COMPUESTO DE UNA PIRIMIDINONAS SUSTITUIDA,COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y EL USO DE DICHO COMPUESTO Y DE DICHA COMPOSICIoN EN LA FABRICACIoN DE MEDICAMENTOS uTILES PARA LA INHIBICION SELECTIVA DE LA CASCADA DE COAGULACIoN - Google Patents

COMPUESTO DE UNA PIRIMIDINONAS SUSTITUIDA,COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y EL USO DE DICHO COMPUESTO Y DE DICHA COMPOSICIoN EN LA FABRICACIoN DE MEDICAMENTOS uTILES PARA LA INHIBICION SELECTIVA DE LA CASCADA DE COAGULACIoN

Info

Publication number
AR030021A1
AR030021A1 ARP000102446A ARP000102446A AR030021A1 AR 030021 A1 AR030021 A1 AR 030021A1 AR P000102446 A ARP000102446 A AR P000102446A AR P000102446 A ARP000102446 A AR P000102446A AR 030021 A1 AR030021 A1 AR 030021A1
Authority
AR
Argentina
Prior art keywords
composition
manufacture
coagulation cascade
compound
pharmaceutical composition
Prior art date
Application number
ARP000102446A
Other languages
English (en)
Inventor
Michael S South
Ashton Hamme
William Neumann
Darin E Jones
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR030021A1 publication Critical patent/AR030021A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuesto de pirimidinona sustituido de formula (1) o una sal aceptable para uso farmacéutico del mismo, donde los sustituyentes son tal como se describen en la memoria descriptiva y reivindicaciones; composicion farmacéutica que lo comprende y el uso de dichos compuestos y composiciones en la fabricacion de medicamentos utiles como inhibidores de serina proteasas de la cascada de coagulacion y para el tratamiento y prevencion de diversas afecciones tromboticas que incluyen enfermedades de la arteria coronaria y enfermedades cerebrovasculares.
ARP000102446A 1999-05-19 2000-05-19 COMPUESTO DE UNA PIRIMIDINONAS SUSTITUIDA,COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y EL USO DE DICHO COMPUESTO Y DE DICHA COMPOSICIoN EN LA FABRICACIoN DE MEDICAMENTOS uTILES PARA LA INHIBICION SELECTIVA DE LA CASCADA DE COAGULACIoN AR030021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13479499P 1999-05-19 1999-05-19

Publications (1)

Publication Number Publication Date
AR030021A1 true AR030021A1 (es) 2003-08-13

Family

ID=22465042

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102446A AR030021A1 (es) 1999-05-19 2000-05-19 COMPUESTO DE UNA PIRIMIDINONAS SUSTITUIDA,COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y EL USO DE DICHO COMPUESTO Y DE DICHA COMPOSICIoN EN LA FABRICACIoN DE MEDICAMENTOS uTILES PARA LA INHIBICION SELECTIVA DE LA CASCADA DE COAGULACIoN

Country Status (22)

Country Link
EP (1) EP1178970A1 (es)
JP (1) JP2002544262A (es)
KR (1) KR20010114271A (es)
CN (1) CN1157380C (es)
AR (1) AR030021A1 (es)
AU (2) AU771718B2 (es)
BR (1) BR0010758A (es)
CA (1) CA2373614A1 (es)
CZ (1) CZ20014116A3 (es)
EA (1) EA004867B1 (es)
HU (1) HUP0201242A3 (es)
IL (1) IL146243A0 (es)
MX (1) MXPA01011804A (es)
NO (1) NO20015604L (es)
NZ (1) NZ514874A (es)
PE (1) PE20010229A1 (es)
PL (1) PL352827A1 (es)
SK (1) SK15852001A3 (es)
TW (1) TWI222445B (es)
UY (1) UY26156A1 (es)
WO (1) WO2000069832A1 (es)
ZA (2) ZA200109339B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
KR20010113969A (ko) * 1999-05-19 2001-12-28 추후보정 항응고제로서의 치환된 폴리시클릭 아릴 및 헤테로아릴우라실
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6852761B2 (en) 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
CA2405561A1 (en) 2000-04-05 2001-10-18 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
EP1268428A2 (en) 2000-04-05 2003-01-02 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
WO2001087851A1 (en) * 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
MXPA03004458A (es) 2000-11-20 2005-01-25 Pharmacia Corp Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion.
WO2003029216A1 (en) 2001-10-03 2003-04-10 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
WO2003029224A1 (en) * 2001-10-03 2003-04-10 Pharmacia Corporation 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
AU2002367752A1 (en) 2001-10-03 2003-11-17 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
JP2005532268A (ja) 2002-02-22 2005-10-27 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換されたピリミジノンおよびピリミジンチオン
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7217794B2 (en) 2003-04-02 2007-05-15 Daiamed, Inc. Compounds and methods for treatment of thrombosis
US7182738B2 (en) 2003-04-23 2007-02-27 Marctec, Llc Patient monitoring apparatus and method for orthosis and other devices
CA2610400A1 (en) * 2005-06-07 2006-12-14 Pharmacopeia, Inc. Azinone and diazinone v3 inhibitors for depression and stress disorders
CN104311537B (zh) * 2014-09-19 2016-08-24 广东东阳光药业有限公司 含有嘧啶酮乙酰基取代基吡唑类化合物及其组合物及用途
AU2020396565C1 (en) * 2019-12-04 2025-05-15 Omeros Corporation MASP-2 inhibitors and methods of use
CN115779953B (zh) * 2022-12-19 2024-06-21 中南大学 铜负载碳基单原子材料及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
US5948785A (en) * 1995-04-27 1999-09-07 The Green Cross Corporation Heterocyclic amide compounds and pharmaceutical use of the same

Also Published As

Publication number Publication date
AU771718B2 (en) 2004-04-01
UY26156A1 (es) 2000-12-29
BR0010758A (pt) 2003-06-10
HUP0201242A2 (hu) 2002-12-28
TWI222445B (en) 2004-10-21
EA200101214A1 (ru) 2002-06-27
KR20010114271A (ko) 2001-12-31
NZ514874A (en) 2004-11-26
AU2004202375A1 (en) 2004-06-24
AU4973400A (en) 2000-12-05
ZA200400448B (en) 2004-09-29
EP1178970A1 (en) 2002-02-13
EA004867B1 (ru) 2004-08-26
SK15852001A3 (sk) 2003-06-03
HUP0201242A3 (en) 2003-02-28
WO2000069832A1 (en) 2000-11-23
PL352827A1 (en) 2003-09-08
NO20015604L (no) 2002-01-11
IL146243A0 (en) 2002-07-25
ZA200109339B (en) 2004-05-26
PE20010229A1 (es) 2001-03-07
CN1351593A (zh) 2002-05-29
NO20015604D0 (no) 2001-11-16
CZ20014116A3 (cs) 2002-06-12
CN1157380C (zh) 2004-07-14
CA2373614A1 (en) 2000-11-23
JP2002544262A (ja) 2002-12-24
MXPA01011804A (es) 2003-09-04

Similar Documents

Publication Publication Date Title
AR030021A1 (es) COMPUESTO DE UNA PIRIMIDINONAS SUSTITUIDA,COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y EL USO DE DICHO COMPUESTO Y DE DICHA COMPOSICIoN EN LA FABRICACIoN DE MEDICAMENTOS uTILES PARA LA INHIBICION SELECTIVA DE LA CASCADA DE COAGULACIoN
AR029635A1 (es) Compuesto derivado de una piridona policiclica sustituida, composicion farmaceutica que lo comprende y el uso de dicho compuesto y de dicha composicion en la fabricacion de medicamentos utiles para la inhibicion selectiva de la cascada de coagulacion
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
AR005053A1 (es) Compuestos de difenilhexano, un procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos, y procedmientos para la manufactura de medicamentos para inhibir la infeccion de hiv
SV2004001414A (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion. pc20535
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
PA8551001A1 (es) Nuevos compuestos
AR063555A1 (es) Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos
AR029752A1 (es) Compuesto derivado de pirazinona policiclica, sustituida, composicion que lo comprende y el uso,de dicha composicion y de dicho compuesto en la fabricacion de medicamentos utiles para la inhibicion selectiva de la cascada de coagulacion
ES2181614T3 (es) Sulfonilfenilheterociclos sustituidos como inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
AR032136A1 (es) Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY26157A1 (es) Aril y heteroaril policíclicos sustituidos útiles para la i nhibición selectiva de la cascada de coagulación
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
CO2023015244A2 (es) Inhibidores heteroaromáticos bicíclicos de la klk5
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
MX9306666A (es) Nuevas azetidinonas substituidas como agentes antiinflamatorios y antidegenerativos.
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
MX2024009773A (es) Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.
UY27399A1 (es) Proceso para la preparación de quinazolinas
AR028987A1 (es) Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad

Legal Events

Date Code Title Description
FB Suspension of granting procedure